Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
266 participants
INTERVENTIONAL
2019-09-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ATG group
ATG group refers to treatment with a protocol including low-dose ATG, CsA, short-term MTX and MMF as GVHD prophylaxis.
ATG
In ATG group, ATG will be intravenously infused via a central venous catheter in day -1 at a dose of 2.5mg/kg.
CsA
In both groups, CsA will be intravenously infused from day -9 and the dose was adjusted based on the concentration.
MTX
In both groups, MTX will be intravenously on days +1(15mg), +3(10mg) and +6(10mg).
MMF
In both groups, MMF will be administrated at a dose of 1.0g/d.
non-ATG group
Non-ATG group refers to treatment with a protocol including CsA, short-term MTX and MMF as GVHD prophylaxis.
CsA
In both groups, CsA will be intravenously infused from day -9 and the dose was adjusted based on the concentration.
MTX
In both groups, MTX will be intravenously on days +1(15mg), +3(10mg) and +6(10mg).
MMF
In both groups, MMF will be administrated at a dose of 1.0g/d.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ATG
In ATG group, ATG will be intravenously infused via a central venous catheter in day -1 at a dose of 2.5mg/kg.
CsA
In both groups, CsA will be intravenously infused from day -9 and the dose was adjusted based on the concentration.
MTX
In both groups, MTX will be intravenously on days +1(15mg), +3(10mg) and +6(10mg).
MMF
In both groups, MMF will be administrated at a dose of 1.0g/d.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. MSD transplant recipient
3. Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
Exclusion Criteria
2. Patients with any conditions not suitable for the trial (investigators' decision)
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanfang Hospital, Southern Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Qifa Liu
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Qifa Liu
Role: PRINCIPAL_INVESTIGATOR
Nanfang Hospital, Southern Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ren Lin
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ATG in HLA-matched HSCT-2019
Identifier Type: -
Identifier Source: org_study_id